

# CLL trials registry for improvement in the long-term follow-up of CLL patients in European Trials: an ERIC Initiative

Peter Hillmen

10<sup>th</sup> June 2010

# Concept of the CLL Clinical Trials Registry


## Purpose of registry:

- Offering long-term FU service
- Allowing wider analysis including meta-analysis and assessment of responses to subsequent treatments

## Concept:

- Web-based system with simple Registry data annually
- National register/ co-ordinating centre
- Executive Committee drawn from European Trial groups
- Registry needs to be a "stand alone" NGO (non-government organisation) → contracts, legal standing, etc.
- ERIC is the parent organisation

# Structure of the CLL Clinical Trials Registry



# Concept of the CLL Clinical Trials Registry

## CLL Trials Executive Committee:

- Peter Hillmen, Barbara Eichhorst, Vincent Levy, Eva Kimby, Tadeuz Robak, Robin Foa, Christian Geissler
- First Meeting at Frankfurt Airport, 12<sup>th</sup> Feb 2010

## Synopsis:

- Produced and distributed to 5 pharmaceutical companies with invite to participate as Founding Members
- Roche, GSK, Genzyme, Mundipharma/Napp and Celgene
- Total funding €2.5million over 3 years
  - Approximately €200,000/year/company for 3 years
- Meetings at EHA regarding responses from various companies



Clinical Research